See more : Immutable Holdings Inc. (IHLDF) Income Statement Analysis – Financial Results
Complete financial analysis of Nextage Therapeutics Ltd (NXTG.TA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nextage Therapeutics Ltd, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Dragoneer Growth Opportunities Corp. II (DGNS) Income Statement Analysis – Financial Results
- Exco Technologies Limited (XTC.TO) Income Statement Analysis – Financial Results
- EPR Properties (EPR-PE) Income Statement Analysis – Financial Results
- Airship AI Holdings, Inc. (AISPW) Income Statement Analysis – Financial Results
- PT DCI Indonesia Tbk (DCII.JK) Income Statement Analysis – Financial Results
Nextage Therapeutics Ltd (NXTG.TA)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.nxtg.co.il/
About Nextage Therapeutics Ltd
Nextage Therapeutics Ltd develops cannabinoid-based products. The company is based in Ness Ziona, Israel.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|---|---|---|
Revenue | 876.00K | 0.00 | 91.00K | 191.00K | 297.00K | 383.00K | 405.00K | 28.00K |
Cost of Revenue | 651.00K | 0.00 | 75.00K | 154.00K | 90.00K | 87.00K | 134.00K | 12.00K |
Gross Profit | 225.00K | 0.00 | 16.00K | 37.00K | 207.00K | 296.00K | 271.00K | 16.00K |
Gross Profit Ratio | 25.68% | 0.00% | 17.58% | 19.37% | 69.70% | 77.28% | 66.91% | 57.14% |
Research & Development | 976.00K | 1.85M | 2.06M | 808.00K | 1.10M | 6.29M | 2.79M | 3.05M |
General & Administrative | 1.29M | 1.76M | 1.20M | 800.00K | 1.94M | 2.29M | 2.11M | 1.92M |
Selling & Marketing | 120.00K | 201.00K | 156.00K | 33.00K | 10.00K | 16.00K | 42.00K | 55.00K |
SG&A | 1.41M | 1.96M | 1.35M | 833.00K | 1.95M | 2.30M | 2.15M | 1.98M |
Other Expenses | 1.82M | 19.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 4.21M | 5.85M | 6.47M | 5.16M | 2.05M | 9.64M | 6.20M | 7.17M |
Cost & Expenses | 4.86M | 5.85M | 6.54M | 5.31M | 2.14M | 9.72M | 6.33M | 7.18M |
Interest Income | -159.00K | 19.00K | 176.00K | 0.00 | 0.00 | 589.00K | 5.00K | -1.35M |
Interest Expense | 50.00K | 25.00K | 159.00K | 106.00K | 241.00K | 0.00 | 27.00K | 263.00K |
Depreciation & Amortization | 128.00K | 57.00K | 190.00K | 96.00K | 161.00K | 4.44M | 820.00K | 712.00K |
EBITDA | -4.03M | -5.90M | -7.58M | -15.87M | -4.40M | -4.32M | -5.06M | -7.78M |
EBITDA Ratio | -459.47% | 0.00% | -6,986.81% | -6,750.79% | -567.34% | -1,127.94% | -1,265.93% | -27,800.00% |
Operating Income | -3.99M | -5.85M | -7.68M | -15.78M | -4.40M | -10.05M | -6.62M | -7.15M |
Operating Income Ratio | -455.14% | 0.00% | -8,437.36% | -8,262.30% | -1,482.83% | -2,624.02% | -1,633.58% | -25,539.29% |
Total Other Income/Expenses | -216.00K | -140.00K | -255.00K | -185.00K | 2.34M | 1.31M | 740.00K | -1.61M |
Income Before Tax | -4.20M | -5.99M | -7.93M | -15.97M | -2.09M | -8.74M | -5.88M | -8.76M |
Income Before Tax Ratio | -479.79% | 0.00% | -8,717.58% | -8,359.16% | -702.69% | -2,282.25% | -1,450.86% | -31,282.14% |
Income Tax Expense | 0.00 | -115.00K | 925.00K | 2.68M | 2.56M | 1.28M | 525.00K | -1.36M |
Net Income | -3.88M | -5.99M | -7.73M | -15.97M | -2.09M | -8.74M | -5.73M | -8.75M |
Net Income Ratio | -442.81% | 0.00% | -8,492.31% | -8,359.16% | -703.03% | -2,280.68% | -1,415.31% | -31,235.71% |
EPS | -0.13 | 0.00 | -0.30 | -1.40 | -1.15 | -6.88 | -6.98 | -18.28 |
EPS Diluted | -0.13 | 0.00 | -0.30 | -1.40 | -1.15 | -6.88 | -6.98 | -18.28 |
Weighted Avg Shares Out | 29.18M | 0.00 | 26.03M | 11.43M | 1.82M | 1.27M | 821.00K | 478.48K |
Weighted Avg Shares Out (Dil) | 29.18M | 0.00 | 26.03M | 11.43M | 1.82M | 1.27M | 821.00K | 478.48K |
Source: https://incomestatements.info
Category: Stock Reports